The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis

被引:12
|
作者
Wang, Bi-Cheng [1 ]
Xiao, Bo-Ya [2 ]
Lin, Guo-He [3 ]
Wang, Chang [4 ]
Liu, Quentin [5 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Hubei, Peoples R China
[2] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China
[3] Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Hefei 230601, Anhui, Peoples R China
[4] Univ Bern, Inst Anat, CH-3012 Bern, Switzerland
[5] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
关键词
Induction chemotherapy; Concurrent chemoradiotherapy; Survival; Nasopharyngeal carcinoma; Meta-analysis; INTENSITY-MODULATED RADIOTHERAPY; RANDOMIZED PHASE-II; NEOADJUVANT CHEMOTHERAPY; STAGE-II; CISPLATIN; MULTICENTER; DOCETAXEL; CHILDREN; SURVIVAL; OUTCOMES;
D O I
10.1186/s12885-020-06912-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundInduction chemotherapy (IC) combined with concurrent chemoradiotherapy (CCRT) has been recommended as the first-line therapy for locoregional nasopharyngeal carcinoma (NPC). Due to the different chemotherapeutic drugs used in the IC and CCRT, the results remain controversial.MethodsPubMed, EMBASE, Web of Science, and Cochrane Library databases were systematically retrieved to search potentially eligible clinical trials up to Sep 11, 2019. Eligible studies were registered and prospective randomized controlled clinical trials.ResultsFrom 526 records, nine articles including seven randomized controlled clinical trials were eligible, with a total of 2311 locoregional advanced NPC patients. IC+CCRT had significantly lower risks of death (3-year hazard ratio [HR]: 0.70, 95% confidence interval [CI] 0.55-0.89, p=0.003; 5-year HR: 0.77, 95% CI 0.62-0.94, p=0.01), disease progression (3-year HR: 0.67, 95% CI 0.55-0.80, p<0.001; 5-year HR: 0.70, 95% CI 0.58-0.83, p<0.0001), distant metastasis (3-year HR: 0.58, 95% CI 0.45-0.74, p<0.0001; 5-year HR: 0.69, 95% CI 0.55-0.87, p=0.001) and locoregional relapse (3-year HR: 0.69, 95% CI 0.50-0.95, p=0.02; 5-year HR: 0.66, 95% CI 0.51-0.86, p=0.002) than CCRT. Compared with CCRT, IC+CCRT showed higher relative risks of grade 3 or more neutropenia, thrombocytopenia, nausea, vomiting and hepatotoxicity throughout the course of treatment, and higher relative risks of grade<greater than or equal to>3 thrombocytopenia and vomiting during CCRT.ConclusionIC combined with CCRT significantly improved the survival in locoregional advanced NPC patients. Moreover, toxicities were well tolerated during IC and CCRT. Further clinical trials are warranted to confirm the optimal induction chemotherapeutic regimen in the future.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma
    Xu, Yao-Can
    Chen, Kai-Hua
    Liang, Zhong-Guo
    Zhu, Xiao-Dong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Adjuvant capecitabine in advanced nasopharyngeal carcinoma following concurrent chemoradiotherapy: A meta-analysis and systematic review
    Velasco, Rogelio Nona
    Ladrera, Guia Elena Imenda Rodrigu
    Imasa, Marcelo Severino Bulauitan
    King, Rich Ericson Chan
    Tan, Harold Nathan
    Kanesvaran, Ravindran
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy
    Mott, Frank E.
    Ferrarotto, Renatta
    Nguyen, Theresa
    Phan, Jack
    ORAL ONCOLOGY, 2018, 81 : 75 - 80
  • [34] The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
    Zhou, R.
    Zhu, J.
    Chen, X.
    Liu, Y.
    Wang, Y.
    Zhang, T.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 429 - 439
  • [35] The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
    R. Zhou
    J. Zhu
    X. Chen
    Y. Liu
    Y. Wang
    T. Zhang
    Clinical and Translational Oncology, 2020, 22 : 429 - 439
  • [36] INDUCTION CHEMOTHERAPY PLUS CONCURRENT CHEMORADIOTHERAPY VERSUS CONCURRENT CHEMORADIOTHERAPY ALONE IN PATIENTS WITH LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA: PRELIMINARY RESULTS OF A PHASE 3 MULTICENTRE RANDOMISED CONTROLLED TRIAL
    Ma, J.
    Chen, N. -Y.
    Zhang, N.
    Hu, G. -Q.
    Sun, Y.
    Chen, X. -Z.
    Li, J. -G.
    Zhu, X. -D.
    Hu, C. -S.
    Xu, X. -Y.
    Sun, Y.
    Xie, F. -Y.
    Hua, W. -H.
    Guo, L.
    Mo, H. -Y.
    Guo, Y.
    Chen, L.
    Li, W. -F.
    Liu, M. -Z.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E3 - E4
  • [37] Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
    Setakornnukul, Jiraporn
    Thephamongkhol, Kullathorn
    BMC CANCER, 2018, 18
  • [38] Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma
    Luo, Haiqing
    He, Jiaqi
    Yi, Guihua
    Tang, Haifeng
    Yang, Donghong
    Li, Haiwen
    Yu, Ying
    Chen, Zihong
    Zhan, Dechao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
    Jiraporn Setakornnukul
    Kullathorn Thephamongkhol
    BMC Cancer, 18
  • [40] The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma A meta-analysis of randomized controlled trials
    Wang, Peirong
    Zhang, Mingwei
    Ke, Chunlin
    Cai, Chuanshu
    MEDICINE, 2020, 99 (10) : E19360